Increasing the dose of somatostatin analogues of in patients with active form of acromegaly: literature review and prospects for application


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the data of foreign studies on the effectiveness and safety of escalation of dose of somatostatin analogues in patients with active form of acromegaly, who received standard doses of drugs. Increase in the dose of lanreotide allows achieving biochemical control in 27.6% of patients with previously uncontrolled acromegaly. Moreover, the drug has a favorable safety profile, and dose escalation does not adversely affect carbohydrate metabolism.

Full Text

Restricted Access

About the authors

M. B Antsiferov

SBHCI “Endocrinological Dispensary" of Moscow Healthcare Department

Zh. E Belaya

FSBI “National Medical Research Center of Endocrinology" of RMH

Email: jannabelaya@gmail.com
MD, Chief Researcher, Head of the Department of Neuroendocrinology and Osteopathy

References

  1. Biermasz N.R., Pereira A.M., Smit J.W.A., Romijn J.A., Roelfsema F Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. J Clin. Endocrinol. Metab. 2005;90(5):2731-39.
  2. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors Influencing Mortality in Acromegaly J. Clin. Endocrinol. Metab. 2004;189(2):667-74.
  3. Дедов И.И., Мельниченко ГА. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей. М., 2012. 80 c.
  4. Анциферов М.Б., Пронин В.С., Алексеева Т.М., Дорофеева Л.Г. Московский регистр больных гипофизарным гигантизмом и акромегалией. Методические рекомендации. М, 2013. 26 с.
  5. Рожинская Л.Я. Регистры и мониторинг заболеваний гипоталамо-гипофизарной области. Эффективная фармакотерапия. Эндокринология. 2014;3(27).
  6. Mestron A., Webb S.M., Astorga R., Benito P, Catala M., Gaztambide S. Epidemiology, clinical characteristics, outcome, mor-bidity and mortality in acromegaly basel on the Spanish Acromegaly Registry (Registro Es-panol de Acromegalia, REA). Eur J. Endocrinol. 2004;151:1-9.
  7. Reincke M., Petersenn S., Buchfelder M., et al. The German Acromegaly Registry: description of the database and initial results. Experiment. Clin. Endocrinol. Diabetes.2006;114:498-505.
  8. Holdaway I.M. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 2008;159(2):89-95.
  9. Kyriakakis N. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-year prospective study Clin. Endocrinol. (Oxf). 2017;86(6):806-15.
  10. Melmed S., Colao A., Barkan A., et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 2009;94(5):1509-17.
  11. Katznelson L., Laws E.R., Melmed S., Molitch M.E., Murad M.H., Utz A., Wass J.A. Acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014;99(11).
  12. Дедов И.И., Молитвословова Н.Н., Рожинская Л.Я., Мельниченко ГА. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии. Ж. Проблемы эндокринологии. 2013;59:4-18.
  13. Мельниченко Г.А., Попович В., Рожинская Л.Я., Белая Ж.Е. Медикаментозная терапия болезни Иценко-Кушинга. Современное состояние проблемы. Проблемы эндокринологии. 2014;60(6):29-37.
  14. Аметов А.С., Пронин В.С. Болезнь Пьера Мари. История и современность Эндокринология: новости, мнения, обучение. 2017;1.
  15. AACE Acromegaly Guidelines: Executive Summary, Endocr. Pract. 2011;17(4).
  16. Melmed S. Guidelines for Acromegaly Management: An Update. J. Clin. Endocrinol. Metab. 2009;94(5):1509-17.
  17. Giustina A. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 2017.
  18. Giustina A. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 2009;161:331-38.
  19. Wuster C., Both S., Cordes U., et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J. Med. Case Reports. 2010;4:85.
  20. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary.2011;14(2):184-93.
  21. Gadelha M.R., Bronstein M.D Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875-84.
  22. Abreu A., Tovar A.P., Castellanos R., et al. Challenges in the diagnosis and management of ac-romegaly: a focus on comorbidities. Pituitary. 2016; 19(4):448-57.
  23. Colao A., Baldelli R., Marzullo P., et al. Systemic hypertension and impaired glucosetolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 2000;85:193-99.
  24. Dreval A.V, Trigolosova I.V., Kovalyova Y.A., et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocrol. Connect. 2014;3(2):93-8.
  25. Древаль А.В., Триголосова И.В., Виноградова А.В. Механизмы нарушений углеводного обена при акромегалии в зависимости от лечения. Проблемы эндокринологии. 2015;1:23-30.
  26. Caron PJ. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study Clinical Endocrinology 2016.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies